Retlirafusp alfa combined with platinum-based chemotherapy as the first-line treatment for advanced NSCLC with negative driver genes mutations

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 5f55b0b79904a33b5646d06130fdfb70d3d7661e
First added on: Oct 10, 2026